News Releases

Date	Title	Additional Formats
May 25, 2022	Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 24, 2022	Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
May 17, 2022	Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
May 10, 2022	Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 4, 2022	Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 3, 2022	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
April 26, 2022	Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
April 1, 2022	Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
March 22, 2022	Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
March 14, 2022	Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis